Levetiracetam Ethypharm

Levetiracetam, the active ingredient in Levetiracetam Ethypharm, is a Anticonvulsant presented as a intravenous solution for intravenous use. It treats partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy and is administered under medical supervision as part of standard epilepsy management protocols.

GNH USA supplies Levetiracetam Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Levetiracetam is an antiepileptic drug used to control various seizure types.

Partial-onset seizures: reduces seizure frequency in patients with focal epilepsy. Generalized tonic-clonic seizures: helps achieve seizure freedom in patients with primary generalized epilepsy. Myoclonic seizures: diminishes myoclonic jerks and improves daily functioning in affected individuals.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Suicidal thoughts or behavior - Severe skin rash - Respiratory depression (rare)

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: monitor liver function tests. - Pregnancy: risk unknown; use only if benefits outweigh risks. - Known hypersensitivity: avoid administration. - Concomitant antiepileptics: monitor for additive CNS effects. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Levetiracetam has a relatively low interaction profile, but certain drugs may affect its plasma levels.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam concentrations. - Phenobarbital: may lower levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Phenytoin: modest reduction in levetiracetam levels. - Valproic acid: may increase risk of central nervous system depression. - Alcohol: can enhance sedation and dizziness. - Other antiepileptics: monitor for cumulative side‑effects.